Hubungan Kadar Interleukin 6 (IL-6) dengan Derajat Aktivitas Penyakit (SLEDAI-2K) dan Manifestasi Kerusakan Renal-Non-Renal Penderita Lupus Eritematosus Sistemik
Penelitian
DOI:
https://doi.org/10.55175/cdk.v53i01.1596Kata Kunci:
Derajat aktivitas penyakit, kadar interleukin-6, kerusakan renal-non-renal, lupus eritematosus sistemikAbstrak
Pendahuluan: Lupus eritematosus sistemik (LES) merupakan penyakit autoimun kronis yang bersifat heterogen dan kompleks. Beberapa penelitian mengaitkan kadar interleukin 6 (IL-6) dan LES. Penelitian ini mencari hubungan kadar IL-6 terhadap derajat aktivitas penyakit
dan manifestasi kerusakan renal-non-renal pada LES. Metode: Penelitian retrospektif cross-sectional pada 67 orang terdiagnosis LES berdasarkan kriteria SLICC 2012/ACR EULAR 2019 minimal 6 bulan di Poliklinik Reumatologi RS Adam Malik selama bulan Juni hingga
Agustus 2023 yang memenuhi kriteria inklusi dan eksklusi. Penilaian manifestasi kerusakan renal-non-renal menggunakan SLICC damage index-SDI score dan derajat aktivitas penyakit diukur menggunakan SLEDAI-2K. Hasil: Median kadar IL-6 tertinggi dengan nilai 87,32 pg/mL didapat pada kelompok pasien remisi, sedangkan median kadar IL-6 terendah dengan nilai 46,05 pg/mL didapat
pada pasien derajat ringan. Tidak ditemukan hubungan signifikan antara kadar IL-6 dan derajat aktivitas penyakit LES (p = 0,158). Nilai median interleukin-6 kelompok subjek dengan kerusakan renal adalah 71,95 pg/mL, pada kelompok subjek dengan kerusakan nonrenal adalah 53,05 pg/mL. Terdapat hubungan signifikan antara kadar interleukin-6 dan kerusakan renal pada pasien SLE (p = 0,045). Simpulan: Tidak ditemukan hubungan antara kadar IL-6 dan derajat aktivitas penyakit (p = 0,158), namun terdapat hubungan signifikan antara kadar IL-6 dan kerusakan renal (p = 0,045).
Unduhan
Referensi
Jordan N, D’Cruz D. Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications. Ther Adv Musculoskelet Dis. 2015;7(6):234–46. doi: 10.1177/1759720X15601805.
Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17(9):515–32. doi: 10.1038/s41584-021-00668-1.
Zhu JL, Black SM, Chong BF. Role of biomarkers in the diagnosis and prognosis of patients with cutaneous lupus erythematosus. Ann Transl Med. 2021;9(5):429. doi: 10.21037/atm-20-5232.
Sachinidis A, Xanthopoulos K, Garyfallos A. Age-associated B cells (ABCs) in the prognosis, diagnosis and therapy of systemic lupus erythematosus (SLE). Mediterr J Rheumatol. 2020;31(3):311. doi: 10.31138/mjr.31.3.311.
Aringer M, Johnson SR. Classifying and diagnosing systemic lupus erythematosus in the 21st century. Rheumatology 2020;59(Suppl 5):v4–11. doi: 10.1093/rheumatology/keaa379.
Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2022;ard-2022-223035. doi: 10.1136/ard-2022-223035.
Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295–a016295. doi: 10.1101/cshperspect.a016295.
Ding J, Su S, You T, Xia T, Lin X, Chen Z, et al. Serum interleukin-6 level is correlated with the disease activity of systemic lupus erythematosus: a meta-analysis. Clinics. 2020;75:e1801. doi: 10.6061/clinics/2020/e1801.
Ghazali WSW, Daud SMM, Mohammad N, Wong KK. SLICC damage index score in systemic lupus erythematosus patients and its associated factors. Medicine (Baltimore). 2018;97(42):e12787. doi: 10.1097/MD.0000000000012787.
Familia AC, Yuliasih Y, Rahmawati LD. Correlation between serum IL-6 level and Th17/Treg ratio with systemic lupus erythematosus disease activity. Biomol Health Sci J. 2019;2(2):107. doi: 10.20473/bhsj.v2i2.15768.
Kambayana G, Pulcheria M, Widiana IGR. Correlation between serum interleukin-6 with glomerular filtration rate in systemic lupus erythematosus. J Penyakit Dalam Udayana. 2019;3(1):22–5. https://doi.org/10.36216/jpd.v3i1.65.
Bruce IN, Urowitz M, van Vollenhoven R, Aranow C, Fettiplace J, Oldham M, et al. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus. 2016;25(7):699–709. doi: 10.1177/0961203315625119.
Fanouriakis A, Adamichou C, Koutsoviti S, Panopoulos S, Staveri C, Klagou A, et al. Low disease activity— irrespective of serologic status at baseline—associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study Semin Arthritis Rheum. 2018 Dec;48(3):467-474. doi: 10.1016/j.semarthrit.2018.02.014.
Bakshi J, Segura BT, Wincup C, Rahman A. Unmet needs in the pathogenesis and treatment of systemic lupus erythematosus. Clin Rev Allerg Immunol. 2018;55(3):352–67. doi: 10.1007/s12016-017-8640-5.
Kono M, Nagafuchi Y, Shoda H, Fujio K. The impact of obesity and a high-fat diet on clinical and immunological features in systemic lupus erythematosus. Nutrients 2021;13(2):504. doi: 10.3390/nu13020504.
Shamekhi Z, Habibagahi Z, Ekramzadeh M, Ghadiri A, Namjoyan F, Saki Malehi A, et al. Body composition and basal metabolic rate in systemic lupus erythematosus patients. Egypt Rheumatol. 2017;39(2):99–102. https://doi.org/10.1016/j.ejr.2016.10.004.
Mathis KW, Venegas-Pont M, Flynn ER, Williams JM, Maric-Bilkan C, Dwyer TM, et al. Hypertension in an experimental model of systemic lupus erythematosus occurs independently of the renal nerves. Am J Physiol-Regul Integr Comp Physiol. 2013;305(7):R711–9. doi: 10.1152/ajpregu.00602.2012.
Zucchi D, Silvagni E, Elefante E, Signorini V, Cardelli C, Trentin F, et al. Systemic lupus erythematosus: one year in review 2023. Clin Exp Rheumatol 2023;41(5):997−1008. https://doi.org/10.55563/clinexprheumatol/4uc7e8.
Muller R. Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities. Rheumatol Int. 2021;41(7):1189−202. doi: 10.1007/s00296-021-04868-6.
Gonzalez LA, Santamaría-Alza Y, Alarcon GS. Organ damage in systemic lupus erythematosus. Rev Colomb Reumatol. 2021;28:66–81. doi: 10.1016/j.rcreu.2021.01.008.
Fujieda Y. Diversity of neuropsychiatric
Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology. 2020;59(Suppl_5):v29–38. doi: 10.1093/rheumatology/keaa382.
Grebenciucova E, VanHaerents S. Interleukin 6: at the interface of human health and disease. Front Immunol. 2023;14:1255533. doi: 10.3389/fimmu.2023.1255533.
Jacob N, Stohl W. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther. 2011;13(4):228. doi: 10.1186/ar3349.
Mak A, Mok CC, Chu WP, To CH, Wong SN, Au TC. Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups. Lupus. 2007;16(1):28–34. doi: 10.1177/0961203306074469.
Osio-Salido E, Manapat-Reyes H. Epidemiology of systemic lupus erythematosus in Asia. Lupus. 2010;19(12):1365–73. doi: 10.1177/0961203310374305.
Idborg H, Oke V. Cytokines as biomarkers in systemic lupus erythematosus: value for diagnosis and drug therapy. Int J Mol Sci. 2021;22(21):11327. doi: 10.3390/ijms222111327.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2026 Yesanopa Sianturi, Deske Muhadi Rangkuti, Andi Raga Ginting
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
